Cargando…

The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas

SIMPLE SUMMARY: Sarcomas are a group of heterogeneous diseases with a poor prognosis and scarce therapeutic options. Innovative approaches based on novel therapeutic targets are eagerly awaited. AXL, a TAM family tyrosine kinase receptor, recently emerged as an interesting target for several type of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Polerà, Nicoletta, Mancuso, Antonia, Riillo, Caterina, Caracciolo, Daniele, Signorelli, Stefania, Grillone, Katia, Ascrizzi, Serena, Hokanson, Craig A., Conforti, Francesco, Staropoli, Nicoletta, Gervasi, Luigia, Di Martino, Maria Teresa, Arbitrio, Mariamena, Nisticò, Giuseppe, Crea, Roberto, Tagliaferri, Pierosandro, Juli, Giada, Tassone, Pierfrancesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046451/ https://www.ncbi.nlm.nih.gov/pubmed/36980534 http://dx.doi.org/10.3390/cancers15061647

Ejemplares similares

A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer
por: Riillo, Caterina, et al.
Publicado: (2023)

miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy
por: Di Martino, Maria Teresa, et al.
Publicado: (2021)

miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2021)

The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma
por: Grillone, Katia, et al.
Publicado: (2022)

TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma
por: Scionti, Francesca, et al.
Publicado: (2023)

Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin
por: Caracciolo, Daniele, et al.
Publicado: (2022)

A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells
por: Riillo, Caterina, et al.
Publicado: (2022)

Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes
por: Scionti, Francesca, et al.
Publicado: (2022)

The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives
por: Caracciolo, Daniele, et al.
Publicado: (2023)

AXL-Receptor Targeted 14FN3 Based Single Domain Proteins (Pronectins™) from 3 Synthetic Human Libraries as Components for Exploring Novel Bispecific Constructs against Solid Tumors
por: Hokanson, Craig A., et al.
Publicado: (2022)

Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity
por: Staropoli, Nicoletta, et al.
Publicado: (2023)

Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats
por: Di Martino, Maria Teresa, et al.
Publicado: (2020)

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma
por: Cucè, Maria, et al.
Publicado: (2019)

Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma
por: Caracciolo, Daniele, et al.
Publicado: (2020)

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia
por: Caracciolo, Daniele, et al.
Publicado: (2021)

Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?
por: Cucinotto, Iole, et al.
Publicado: (2013)

Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma
por: Stamato, Maria Angelica, et al.
Publicado: (2017)

Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice
por: Arbitrio, Mariamena, et al.
Publicado: (2020)

First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis
por: Ciliberto, Domenico, et al.
Publicado: (2023)

MMRF-CoMMpass Data Integration and Analysis for Identifying Prognostic Markers
por: Settino, Marzia, et al.
Publicado: (2020)

Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221
por: Di Martino, Maria Teresa, et al.
Publicado: (2019)

Mouse models of multiple myeloma: technologic platforms and perspectives
por: Rossi, Marco, et al.
Publicado: (2018)

Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice
por: Ascrizzi, Serena, et al.
Publicado: (2023)

Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer’s Achilles’ Heel
por: Caracciolo, Daniele, et al.
Publicado: (2021)

A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics
por: Staropoli, Nicoletta, et al.
Publicado: (2022)

BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?
por: Tagliaferri, Pierosandro, et al.
Publicado: (2009)

DMET-Analyzer: automatic analysis of Affymetrix DMET Data
por: Guzzi, Pietro Hiram, et al.
Publicado: (2012)

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes
por: Agapito, Giuseppe, et al.
Publicado: (2016)

DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine
por: Arbitrio, Mariamena, et al.
Publicado: (2016)

Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study
por: Tassone, Pierfrancesco, et al.
Publicado: (2023)

A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
por: Staropoli, Nicoletta, et al.
Publicado: (2013)

Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report
por: Siciliano, Maria Anna, et al.
Publicado: (2020)

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts
por: Pitari, Maria Rita, et al.
Publicado: (2015)

Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives
por: Arbitrio, Mariamena, et al.
Publicado: (2018)

MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches
por: Amodio, Nicola, et al.
Publicado: (2018)

Non-coding RNAs in cancer: platforms and strategies for investigating the genomic “dark matter”
por: Grillone, Katia, et al.
Publicado: (2020)

DMET(TM) Genotyping: Tools for Biomarkers Discovery in the Era of Precision Medicine
por: Agapito, Giuseppe, et al.
Publicado: (2020)

miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review
por: Di Martino, Maria Teresa, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates
por: Gallo Cantafio, Maria Eugenia, et al.
Publicado: (2016)

From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology
por: Gallo Cantafio, Maria Eugenia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ctscct8t0hb694lu6plni6f7n7